Physician profile
William Lee
NPI 1770019515
$1,196.35
in general payments reported to CMS, 2019-2025
16 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.45 · 2022: $182 · 2023: $209 · 2024: $184 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $252.80 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals Lp | $234.91 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $200.26 | 2021-2024 | Repatha, Otezla |
| Alpha Cognition USA, INC. | $169.00 | 2025 | Zunveyl |
| Otsuka America Pharmaceutical, INC. | $98.95 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $46.75 | 2021-2025 | Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.70 | 2025 | Caplyta |
| Organogenesis INC. | $24.58 | 2024 | |
| Avanir Pharmaceuticals, INC. | $21.87 | 2021 | |
| Dexcom, INC. | $19.66 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $18.09 | 2022 | |
| Sumitomo Pharma America, INC. | $17.72 | 2023 | Gemtesa |
| Insulet Corporation | $17.40 | 2023 | Omnipod |
| Exact Sciences Corporation | $16.26 | 2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $14.12 | 2024 | Ingrezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.